A case of mediastinitis following botulinum toxin type A treatment for achalasia
Abstract
BACKGROUND: A 62-year-old obese, diabetic female underwent endoscopic esophageal injection of botulinum toxin type A (Botox; Allergan, Irvine, CA) for achalasia. The patient presented to her gastroenterologist with chest pain 4 days after the procedure, but no thoracic or gastrointestinal pathologies were identified and the patient was sent home. She presented again the next day with continuing chest pain and newly developed fever. Esophagoduodenoscopy revealed no esophageal leak and a CT scan revealed only mild paraesophageal inflammation. The patient was sent home the same day with antibiotics after a urinalysis suggested presence of a urinary tract infection. The patient presented again 9 days after the procedure with continuing chest pain and fever.
INVESTIGATIONS: Chest radiography, electrocardiography, complete blood count, cardiac enzyme levels, basic metabolic panel, urinalysis, Gastrografin (Bracco Diagnostics Inc, Princeton, New Jersey) and barium swallow study, endoscopy, abdominal and chest CT scans, blood culture and wound culture.
DIAGNOSIS: Ulceration without perforation of the esophageal mucosa in the area of Botox injections. Unilateral pleural effusion and mediastinitis without abscess formation.
MANAGEMENT: Pantoprazole and clonazepam for suspected gastroesophageal reflux and esophageal spasm. Levofloxacin for urinary tract infection. Intravenous antibiotic therapy and acute surgical exploration for possible esophageal rupture. Paraesophageal drain…
How strong is the evidence?
Evidence Hub reads this as a case report, done in people. Its evidence level is 5 of 5 (Very low · case / narrative / animal / in vitro / in silico). Case reports, narrative reviews, and animal, cell or computer-model studies give the weakest evidence for human health.
Read the paper
Related studies
- Association of lower urinary tract symptoms and OAB severity with quality of life and mental health in China, Taiwan and South Korea: results from a cross-sectional, population-based study
- Ten-Day Quadruple Therapy Comprising Low-Dose Rabeprazole, Bismuth, Amoxicillin, and Tetracycline Is an Effective and Safe First-Line Treatment for Helicobacter pylori Infection in a Population with High Antibiotic Resistance: a Prospective, Multicenter, Randomized, Parallel-Controlled Clinical Trial in China
- The Role of the NLR and PLR in Urinary Tract Infection
- Threat of Antimicrobial Resistance among Pilgrims with Infectious Diseases during Hajj: Lessons Learnt from COVID-19 Pandemic
- Leclercia adecarboxylata urinary tract infection in a patient with bladder cancer and recurrent hematuria
- A Case Series of Staphylococcus lugdunensis Infection in Cancer Patients at an Academic Cancer Institute in the United States
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.